Clinical Trial Search

Primary: Virtual Environment TBI System (VETS) Assessment of Static Posturography — 11; 13.0; 48.4; 19.1 Square Centimeters

Primary: Heart Rate Variability (HRV) — 1439; 2191 ms2

Primary: Composite Definition of Study Success — 65.3; 73.7; 37.4; 69.7 percentage of subjects analyzed — p=0.0021

Primary: Percentage of Participants With ≥50% Pain Reduction on the Numeric Rating Score (NRS) for Pain — 60; 72 percentage of participants — p=0.23

Primary: Occiflex Device Safety — 26 Number of adverse effects

Primary: Percent of Peak Activation (%PA) — 51.72; 61.20; 88.1; 80.80 Percentage of Peak Activation (%PA)

Primary: Neck Disability Index — 17.9; 16.7 units on a scale from 0 to 100 — p=0.641

Primary: Radiographic Fusion — 66; 46; 37; 75 percentage of subjects

Primary: Individual Patient Overall Success — 142; 98 participants

Primary: Changes in Blood Flow Through the Vertebral Artery and Posterior Cerebral and Cerebellar Circulation — 15.5; 15.1; 14.7 cm/s

Primary: Muscle Mass Via Dual-Energy X-ray Absortiometry (DEXA)Scan Data — 6104.45; 6355.3 grams — p=.318

Primary: Graded and Redefined Assessment of Strength, Sensibility and Prehension Test (GRASSP Test) — 4.5; 19.4 score change before and after — p=<0.000

Primary: Number of Participants Showing Improvement or no Further Progression of Motor Deficits at 1 Month Following Radiotherapy — 68; 69 Participants

Primary: Change in Number of Total Collisions (TC) — 2 collisions/crashes

Primary: Number of Participants With Composite Clinical Success (CCS) of Simplify Disc — 68; 132 Participants — p=<.001

Primary: Avoidance of Neck Surgery — 24; 20; 3; 6 Participants

Primary: Neck Pain — 3.8; 3.3; 3.4 cm

Primary: Composite Clinical Success (CCS) Rate of the Simplify® Disc — 153; 105 Participants — p=0.017

Primary: Electromyographic Responses (Active)

Primary: Physical Activity Level at Week 8 — 383; 297 Minutes per week

Primary: C2-C7 Lordosis — 11.0; 10.9 °

Primary: Injection Dispersal Patterns Measured (in cm) in the Superoinferior Directions on Post-injection MRI With a Calibrated Internal Measurement Software. — 14.73 cm

Primary: Swallowing Difficulty — 16; 14; 5; 7 Participants — p=0.036

Primary: Grasp Release Test - Test of Functional Ability to Pick up and Move Objects — 2; 5.5 Number of Completions

Primary: The Percentage of Participants With Reduction of 50% or More of Neck and Arm Pain NRS Score — 49.1; 68.5 percentage of participants

Primary: Rate of Overall Success — 70.4; 63.2 percentage of participants — p=0.995

Primary: Range of Traction Forces — 13.82; 38.3; 65.08; 17.19 Newtons (N)

Primary: Arm and Hand Function as Assessed by Score on the Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) — 64.9; 58.3 score on a scale

Primary: Change in the Occurrence of Dysphagia -Bazaz Scale — 2.17; 3.27 score on a scale

Primary: Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline — 53.0; 52.7; 43.0; 52.1 units on a scale — p=<0.001